about
Treating Immunodeficiency through HSC Gene Therapy.X-linked lymphoproliferative disease due to SAP/SH2D1A deficiency: a multicenter study on the manifestations, management and outcome of the disease.Management options for adenosine deaminase deficiency; proceedings of the EBMT satellite workshop (Hamburg, March 2006).Stepwise phosphorylation of p65 promotes NF-κB activation and NK cell responses during target cell recognition.Sustainable use of continuous positive airway pressure in extremely preterm infants during the first week after deliverySAP gene transfer restores cellular and humoral immune function in a murine model of X-linked lymphoproliferative disease.Gene therapy for primary immunodeficiency.Stem cell transplantation for primary immune deficiency.Gene therapy for haemophagocytic lymphohistiocytosis.Lentivirus technologies for modulation of the immune system.Stem cell transplantation for the treatment of immunodeficiency in children: current status and hopes for the future.Outcome of hematopoietic cell transplantation for DNA double-strand break repair disorders.Severe Epstein-Barr virus infection in primary immunodeficiency and the normal host.Impaired antibacterial autophagy links granulomatous intestinal inflammation in Niemann-Pick disease type C1 and XIAP deficiency with NOD2 variants in Crohn's disease.Natural Killer Cells from Patients with Recombinase-Activating Gene and Non-Homologous End Joining Gene Defects Comprise a Higher Frequency of CD56bright NKG2A+++ Cells, and Yet Display Increased Degranulation and Higher Perforin Content.Corrigendum: Natural Killer Cells from Patients with Recombinase-Activating Gene and Non-Homologous End Joining Gene Defects Comprise a Higher Frequency of CD56bright NKG2A+++ Cells, and Yet Display Increased Degranulation and Higher Perforin ContenOutcome of hematopoietic stem cell transplantation for adenosine deaminase-deficient severe combined immunodeficiency.Hematopoietic stem cell transplant in patients with activated PI3K delta syndrome.T cell gene therapy for perforin deficiency corrects cytotoxicity defects and prevents Haemophagocytic Lymphohistiocytosis manifestations.X-Linked Lymphoproliferative Disease Type 1: A Clinical and Molecular Perspective.Transfer of gene-corrected T cells corrects humoral and cytotoxic defects in patients with X-linked lymphoproliferative disease.CD34+stem cell top-ups without conditioning after initial haematopoietic stem cell transplantation for correction of incomplete haematopoietic and immunological recovery in severe congenital immunodeficienciesInherited p40phox deficiency differs from classic chronic granulomatous diseaseNon-infectious lung disease in patients with adenosine deaminase deficient severe combined immunodeficiencyA Spectrum of Genetic Variants Contributes to Immune Defects and Pathogenesis of Inflammatory Bowel DiseasesTreatment dilemmas in asymptomatic children with primary hemophagocytic lymphohistiocytosisLentiviral gene therapy rescues p47phox chronic granulomatous disease and the ability to fight Salmonella infection in mice
P50
Q34518945-965EAA7D-B49D-4E93-82A1-CF4043571D4BQ36030027-F2560646-EC61-43B0-81E8-F96D2AC68F60Q36735910-39DF2B8E-12FF-4E8A-82A9-E8A92072BADFQ36973848-5A1BDFEF-5E70-45B8-A648-23261C3121B4Q37168232-09A27BDC-EC0C-4E2E-A1C0-6B8D0825CE3BQ37188448-ACE72604-CD98-4962-991F-BE235CAF9118Q37942283-56C3AF0C-BB73-4039-BC31-411FA3A787F2Q38150627-A6C9551E-42D8-4558-92FF-E050FCBA2BE1Q38253184-550C4F5B-ADB0-4086-B1BA-0E29F0B8E240Q38585486-C7DDB9AF-F60D-49A9-870E-90D15DE2D973Q38735833-E8A8364D-696D-4B44-B3AB-BF1B2828BF9DQ38845467-63E86D0C-8B4C-4B68-B9CF-F147D6C9A75FQ38982455-449ADC61-F4CB-4AB9-B4DE-B9891DE9EA23Q39940199-1F0F39CE-27B9-4C12-A1A0-339D14D9A65CQ40109028-5AFEC777-3A19-4B2D-A416-7FE89C38209AQ42377731-8C13B303-EE8C-4D16-9B0B-9087AC0AF22BQ45413952-FDFEF85E-251F-4EDF-8150-A765191747FAQ46449432-FDCE5935-5303-45B9-85AD-35378FA3D027Q47550593-9FF420B8-194C-447F-AAA8-706C1AD2B00BQ52579140-EB091C82-AA20-469D-97D3-385FA5848E7EQ55491376-59A6C527-543E-41FB-A224-0BD720449E9DQ61053885-5561C587-78ED-422D-830B-EECF2A90AE03Q61053904-459F4CDC-C84A-4C17-B03E-A759FA7D39F7Q83476222-5CE63DB0-E0E4-4CBA-B354-12869E55839EQ88590419-3B35AF31-1904-4644-834B-6C6AEB81943FQ90926180-BC767AFF-E400-45C3-BDDF-F21C6FC64B9DQ96348722-5B83CDD7-F063-4A44-BBBC-66E97ABD293C
P50
description
researcher ORCID ID = 0000-0002-2626-5037
@en
name
Claire Booth
@ast
Claire Booth
@en
Claire Booth
@es
Claire Booth
@nl
type
label
Claire Booth
@ast
Claire Booth
@en
Claire Booth
@es
Claire Booth
@nl
prefLabel
Claire Booth
@ast
Claire Booth
@en
Claire Booth
@es
Claire Booth
@nl
P21
P31
P496
0000-0002-2626-5037